Oncology Central

Express approval of immune checkpoint inhibitors: a conflict between science and finance

0

Immune checkpoint inhibitors are new biologic agents currently in the process of revolutionizing cancer care. By blocking pro-inhibitory agents of the immune response, these agents allow for a restitution of the cancer-killing properties of the immune system which will no longer be limited by the tumor’s ability to evade detection. Different agents (anti-CTLA4, anti-PD-1 and anti-PD-L1) were approved in the past few years for different malignancies and in different settings.

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.